Introduction
The discovery of viruses as infectious agents can be directly linked to the development of filtration devices removing all cells and bacteria in the late 19th century. Building on this technical advancement, the Russian biologist Dmitri Ivanovski identified in 1892 a new class of infectious agents causing mottling in tobacco plants.
It took 40 years to isolate and characterize the actual infectious agent, the Tobacco mosaic virus (Lecoq, 2001) . However, Ivanovski's operational definition of a virus as an agent capable of transmitting an infection following filtration provided a simple strategy that became the workhorse of early virologists, which was used extensively to test whether filtrates from disease tissues or body fluids were able to transmit pathological conditions. This approach enabled the Italian physician Giuseppe Ciuffo to identify the viral etiology of human warts in 1907 (Ciuffo, 1907) , a discovery that was not fully appreciated by his contemporaries and remained in the dark until the human papillomaviruses were associated with human cancer in the 1970s. Using this procedure, Peyton Rous at the Rockefeller Institute showed in 1911 that a solid tumor-a spontaneous spindle cell sarcoma arising in chicken in a nearby farm-could be readily transmitted to other healthy chickens using tumor filtrates (Rous, 1911) . This observation led to the identification of the Rous sarcoma virus (RSV) as the first tumor-causing virus (Rous, 1910) . RSV belongs to the same Retroviridae family than the avian leukemia virus (ALV) (Vogt, 2009) , which the Danish scientists Ellerman and Bang had shown to transmit chicken leukemia (Ellermann and Bang, 1908) . Leukemia was not regarded as a malignancy at that time, and hence ALV was not considered a tumor-causing virus (Epstein, 1971) . In spite of the simplicity, elegance and reproducibility of Rous's findings, his work was fiercely debated and argued against by a scientific community that was likely not prepared to grasp the paramount importance of his observation. Ultimately, Rous was awarded the Nobel Prize 55 years later, in 1966, as his discovery set the foundation of our current understanding of experimental and human cancer biology.
Retroviruses share a common genomic structure 5 0 LTR-gag-pol-env-LTR 3 0 . The viral gag gene encodes for structural proteins necessary for virion formation, and pol encodes several enzymatic activities, including the critical reverse transcriptase, whereas env encodes envelope proteins involved in host cell recognition and infection (Coffin et al., 1997) . The long terminal repeats display transcriptional promoting activity and are required for the random integration of the retrotranscribed viral sequences into the host DNA. Intense studies revealed that unlike ALV, RSV included a nonessential extra segment in its 3 0 end, encoding a gene termed src for its ability to induce sarcomas, which was thus considered the first bona fide oncogene (Duesberg and Vogt, 1970) . This information was exploited by Bishop, Varmus and their colleagues, who, using a clever DNA-hybridization strategy, identified avian cellular sequences with homology to the RSV-encoded src. The avian gene related to v-src was termed c-src, and in so doing, they described the first cellular counterpart of a cancer-causing gene or proto-oncogene (Stehelin et al., 1976) . This finding also provided a novel conceptual framework, as it suggested that human cancers might arise from the aberrant expression or alterations in normal human genes, thus setting the stage for contemporary molecular oncology. Indeed, many other transforming retroviruses were identified whose oncogenes encode altered versions of some of the most frequently mutated human cancer genes (Weinberg, 1997) .
Human tumor-associated viruses
Animal acute-transforming retroviruses and their encoded oncogenes were the center of attention in cancer biology in the 1970s and 1980s, as they enabled a wealth of discoveries on the molecular mechanisms involved in cellular transformation. In addition, DNA viruses such as the Murine Polyoma Virus and Simian Vacuolating Virus 40 (SV40) were shown to cause tumors in experimental animals and to transform human cells in culture (reviewed in Howley and Livingston, 2009 ). However, detractors of the field of viral oncology at that time argued that none of these viruses had been related to human cancer, as attempts to identify viruses causing human malignancies had been unsuccessful. That was going to change dramatically just a few years later when the first human tumor viruses were identified. We now know that at least six viruses contribute to human malignancies (Table 1) . Indeed, 10-15% of the cancers worldwide, or over 1.3 million cases of cancer each year resulting in almost a million deaths, can be linked to viral infection (Parkin, 2006) . In this study, we will discuss the emerging information on the molecular events underlying the neoplastic potential of these human tumor-associated viruses.
Epstein-Barr virus
In 1958, Denis Burkitt first described a childhood B-cell malignancy in Uganda, now known as Burkitt's lymphoma, which he suspected to have a viral etiology closely associated with malaria (Burkitt, 1962) . In 1965, Tony Epstein and Yvonne Barr identified herpesvirus particles by electron microscopy in Burkitt's lymphoma cells. This virus was distinct from other previously described herpesviruses and was named the EpsteinBarr virus (EBV) or human herpesvirus 4 (HHV-4) (Epstein et al., 1965) . Currently, we know that EBV is associated with a human benign disease, infectious mononucleosis and with multiple human malignancies, including nasopharyngeal carcinoma, gastric carcinoma, almost half of the cases of Hodgkin's lymphoma and Bcell lymphoma in immunocompromised patients (Javier and Butel, 2008; Parkin, 2006) (Table 1) . EBV infection immortalizes B lymphocytes causing polyclonal proliferation, which could result in the escape of some transformed clones, but the exact mechanism by which EBV causes lymphoproliferation is far from being completely understood. A virally encoded six-span transmembrane protein, latent membrane protein 1 (LMP1), appears to mediate some of the proliferation signals driving the B-cell population expansion (Arvanitakis et al., 1995) . LMP1 acts as a constitutively active receptor that mimics activated CD40, a member of the tumor necrosis factor receptor family (Mosialos et al., 1995) . The cytoplasmic carboxyl terminus of LMP1 has a critical role in EBV-induced B-cell transformation through its binding to a tumor necrosis factor receptorassociated factor and the tumor necrosis factor receptorassociated death domain protein (Brown et al., 2001) . This, in turn, induces the activation of several key signaling molecules such as PI3K, JNK and JAKs leading to the activation of transcription factors including NF-kB, AP-1 and STATs (Kilger et al., 1998) , all of which have been extensively related to human malignancies.
Despite the ability of LMP1 to induce B-cell transformation, it is not expressed in Burkitt's lymphoma cells. In that regard, the proposed role of EBV in Burkitt's lymphoma was initially met with great skepticism (Epstein, 2001) . Finding EVB linked to a particular African tumor, it was quite surprising when ensuing epidemiological studies showed >90% seropositivity in adults worldwide, making this fact initially one of the major arguments for the detractors of EBV-induced tumorigenesis (Epstein, 2001) . Nowadays, however, it is widely accepted that EBV has a central role in African Burkitt's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma, the latter a highly aggressive cancer type that is quite prominent in Southeast Asia (Young and Rickinson, 2004) . This disparity between the widespread EBV infection and the delayed and low incidence of infected individuals developing cancer, such as Burkitt's lymphoma, led to the current view that genetic or environmental factors (for example, parasitic infections such as malaria, nutrition, maturity and status of the immune system and translocation of myc that is frequently found in Burkitt's lymphoma cells) also have a crucial role in the development of this disease (Lombardi et al., 1987) . This example illustrates a general concept in tumor virology, which is that human oncogenic viruses often lead to malignancies with a prolonged latency and in conjunction with other environmental or host-related cooperating events.
Hepatitis B virus
A viral etiology for certain forms of hepatitis had been suspected for years because of the infectious patterns of transmission of this disease. After an unfortunate accident, Blumberg identified in 1965 a blood antigen that reacted with antibodies from patients with hepatitis (Blumberg, 1977) . This antigen was a surface protein of a hepatotropic DNA virus, which was called hepatitis B virus (HBV) (Hirschman et al., 1969) . In most individuals, infection with this virus is asymptomatic or leads to an acute hepatitis after which the infection is cleared by the immune response (Guidotti et al., 1999) . However, HBV infection fails to clear, leading to chronic infection in a large fraction of individuals infected as neonates or young children and in a small percentage of adults. We now know that HBV has a causative role in the majority of the hepatocellular carcinomas (HCC), leading to more than 300 000 deaths every year from a total 350 million people infected worldwide (Kao and Chen, 2002) (Table 1) . A vaccine against HBV was developed in the late 1970s (Buynak et al., 1976) . This provided an effective means to prevent the spread of HVB infection and the subsequent development of HBV-associated HCC, which can therefore be considered the first anticancer vaccine.
HBV possesses an unusual partially double-stranded circular DNA encoding four open-reading frames, each yielding several overlapping and frame-shifted proteins because of the alternative use of start codons. Its pathogenic mechanism is far from being completely understood (Guidotti and Chisari, 2006) . None of the virally encoded proteins has been directly linked to an acutely oncogenic activity, as the interval between the initial viral infection and the development of HCC normally spans several decades. Rather, persistent infection with HVB is associated with varying degrees of chronic liver disease, progressing to cirrhosis and lately HCC (Guidotti and Chisari, 2006) . During this progression, sustained immune-mediated tissue injury, hepatocellular regeneration and continuous inflammation are thought to result in random genetic and chromosomal damage leading to HCC (Nakamoto et al., 1998) . Chronic liver cell injury could be considered as a premalignant state in which increased DNA synthesis, proinflammatory byproducts such as reactive oxygen species, and decreased cellular detoxification and repair functions could result, over an extended period of time, in multiple genetic and chromosomal alterations and ultimately in cancer (Ganem and Prince, 2004) . In a few cases, HBV DNA integration could also have a positional effect a Source: (Parkin, 2006) b Human cancer-associated viruses often lead to malignancies with a prolonged latency and in conjunction with other environmental or host-related cooperating events, including nutritional status, environmental factors, parasitic or viral infection, chronic inflammation, and immunosuppression.
reminiscent of that of some retroviruses when integration occurs in the proximity of oncogenic genes (Wang et al., 1990) . Interestingly, one of the HVB-encoded proteins, X protein, has been proposed to activate several molecular mechanisms involved in proliferation and inflammation, such as the AP-1 and NF-kB pathways, activation of the JAK1, protein kinase C, PI3K and MAPK (Tang et al., 2006) . The X protein has also been described to directly interact and interfere with several transcription factors including CREB, ATF, NF-IL6, EGR1, OCT1 RXR and the p53 tumor suppressor, all of which may participate in HCC progression (Guidotti and Chisari, 2006) .
Hepatitis C virus
A particular subset of transfusion-associated serum hepatitis patients was found to be not infected with HBV (Dienstag et al., 1977) . Interestingly, these patients developed a rather mild hepatitis that gave rise to persistent infection in an elevated percentage of the cases (Thomas et al., 2000) . This disease was associated with a small enveloped virus that Houghton and colleagues identified as an RNA virus of the flaviviridae family in 1989, which was termed the Hepatitis C virus (HCV). A year later, the same group established the link between HCV and HCC and chronic liver disease (Colombo et al., 1989) . There are more than 270 million people infected by HCV worldwide and 20% of them are expected to eventually develop liver complications and cirrhosis, and those will ultimately have a 4-7% annual risk to progress to HCC (Thomas et al., 2000) (Table 1) . The mechanism by which HCV causes liver damage and HCC is not much unlike HBV. It involves sustained liver damage and inflammation by inducing a strong immunological reaction in the liver that ultimately leads to cirrhosis and cancer after several decades of chronic infection. Unfortunately, the development of an effective HCV vaccine has been challenging because of the weak immune response elicited by HCV.
High-risk human papilloma viruses
In 1842, the Italian physician Rigoni-Stern noted that cases of cervical cancer in women were associated with sexual contacts (Gasparini and Panatto, 2009) . Genital warts had also been associated with sexual promiscuity, and so a contagious etiology was suspected, but a demonstration of the contagious nature of genital warts did not arrive until 1907 when Ciuffo observed the transmission of warts using cell-free extracts (Ciuffo, 1907) . To date, more than 130 HPV types have been identified and classified into low-or high-risk groups depending on their likelihood of inducing cervical cancer on persistent infection (zur Hausen, 2009) . HPV is associated with nearly all the carcinomas of the uterine cervix, and in particular, 70% of the cervical cancers are associated with the high-risk HPV types 16 and 18 (Beaudenon et al., 1986; zur Hausen, 2009 ). In most people, infection with HPV is asymptomatic and is cleared within 1 or 2 years in 90% of the cases. However, genital HPV is considered the most common sexually transmitted disease that is responsible for more than 500 000 new annual cases of human cancer worldwide, including those of the cervix, anus, vulva, penis and of the head and neck area and oropharynx (Parkin, 2006; zur Hausen, 2009) (Table 1) .
The molecular pathogenesis of cervical cancer and other HPV-associated cancers is much better understood than for other viral-induced malignancies. Preventive programs set in place worldwide after the establishment of HPV as a causative agent of cervical cancer through the routine Papanicolau test or PAP smear have provided extensive information about the natural history of HPV infection and the development of cervical cancer. It is a lengthy process, spanning normally about 12-15 years, involving chronic inflammation and a multistage complex interaction of the host immune system, in combination with the expression of two viral genes, E6 and E7, followed by integration of the viral DNA into the host genome and a series of epigenetic changes occurring in dysplastic lesions (Kadaja et al., 2009 ). The molecular function of E6 and E7 provided one of the first evidences that human tumor viruses have evolved alternative strategies to induce cell proliferation and transformation. This mechanism was first observed during the analysis of another virus with oncogenic properties in human cells in vitro, the SV40 polyomavirus. Unlike retroviruses, instead of repurposing a hijacked human gene and transforming it into an oncogene, DNA tumor viruses sport genes of exclusive viral origin that are essential for viral replication (Javier and Butel, 2008) . Although no human neoplasms have been associated with SV40 infection, its ability to induce tumors in animal models enabled the identification of a virally encoded protein, large T antigen, harboring potent oncogenic activity. In 1979, molecular studies by Lane and Levine led to the identification of a cellular protein of 53 KDa that interacted strongly with large T and was thus named TP53 (Levine, 1997) . It took several years before the impact of this discovery was fully realized. Vogelstein and Kinzler (2004) reported in 1989 that the TP53 gene is commonly deleted in colorectal cancers, thus raising the possibility that TP53 represented a tumor suppressor gene. This observation was rapidly extended to numerous other cancer types. Indeed, p53 is the most commonly mutated gene in human cancer, being altered in approximately 50% of all human malignancies (Vogelstein and Kinzler, 2004) .
It was a surprising finding that, similar to SV40, HPV viruses have evolved to deploy a similar strategy to induce transformation. The E6 oncogene product associates with a cellular protein of 100 KDa called E6-associated protein (E6-AP) with E3 ubiquitin ligase activity (Scheffner et al., 1993) . Although large T impairs the function of p53 based on physical interaction and inhibition, E6 and E6-AP induce the rapid degradation of p53 through the proteasome pathway on ubiquitination (Scheffner et al., 1993) . Another oncogenic driver in HPV-infected cells is the viral oncogene E7. In 1971, Knudson identified a gene that was mutated in a rare form of a sporadic pediatric cancer, retinoblastoma, which could also be inherited (Knudson, 1971) . These studies led to the hypothesis that cancer development required two sporadic mutations in a single recessive trait, and that tumor progression could be greatly accelerated if one of the mutations was inherited. In the mid 1980s the Rb tumor suppressor gene, responsible for this disease, was identified (Friend et al., 1986) . Led by previous observations on p53, it was rapidly found that its protein product, Rb, is the target for some tumor virus proteins, including the SV40 large T antigen and the E1A protein form of human adenovirus (Dyson et al., 1989a) . HPV-encoded E7 competes with the E2F transcription factor for binding to Rb, releasing E2F and enabling DNA synthesis by entering into the S phase of the cell cycle (Dyson et al., 1989b) . Unscheduled inactivation of the Rb protein triggers a robust antiproliferative response mediated by the p53 protein as a mechanism to abort oncogenic transformation (Hickman et al., 2002) . It is therefore not surprising that viruses such as SV40, Adenovirus and HPV have co-evolved to inactivate both p53 and Rb to induce transformation. Recent studies suggest that E6 can also affect multiple cell-cell adhesion molecules and signaling events (Mantovani and Banks, 2001 ). Ultimately, the recent development of HPV vaccines against some of the high-risk strains, including HPV16 and HPV18, may help reduce the estimated more than 450 000 annual cases of cervical cancer worldwide (zur Hausen, 2009), as well as limiting the emerging spread of HPV-associated oral cancers (Chaturvedi et al., 2008) .
Human T-cell lymphotropic virus (HTLV-1)
The stage for the discovery of the first human oncogenic retrovirus was set in 1977 by Takatsuki and colleagues who studied a particular leukemia termed adult T-cell leukemia (ATL) in Japan (Uchiyama et al., 1977) . Owing to its distinct geographic distribution, an infectious etiology was suspected. In 1980, after many years of failed attempts to isolate human tumor retroviruses by the scientific community, Robert Gallo identified a novel retrovirus in cultured human T-cell lymphoma cells, which was named the human T-cell lymphotropic virus (HTLV-1) (Poiesz et al., 1980) . Between 10 and 20 million people worldwide are infected with HTLV-1 and the prognosis remains poor for ATL patients (Table 1) . In less than 2% of infected individuals, HTLV-1 is also associated with a progressive demyelinating upper motor neuron disease known as HAM/TSP for HTLV-1-associated myelopathy/ Tropical Spastic Paraparesis characterized by sensory and motor deficits, particularly of the lower extremities, incontinence and impotence (Araujo and Silva, 2006 ). The molecular mechanism by which HTLV-1 causes cancer is still under active investigation, but it is clear that it involves the function of a virally encoded essential protein called Tax rather than of insertional mutagenesis that is typical for leukemia-causing animal retroviruses (Yoshida, 2001) . The mechanism by which Tax induces transformation seems to involve the perturbation of several cell growth regulatory pathways, epigenetic mechanisms and interference with the cellular DNA repair apparatus (Yoshida, 2001 ), although only a small proportion of patients would develop ATL after several decades from the initial infection. Similar to EBV's LMP-1, Tax strongly activates the NF-kB, AP-1 and CRE pathways that have a particularly potent pro-proliferative effect on lymphocytes, whereas Tax also interacts with several factors regulating chromatin remodeling, such as HDAC-1 and SWI/SNF, and causes the inhibition of DNA repair mechanisms, thus leading to genomic instability and ultimate transformation (Matsuoka and Jeang, 2007) . There is no vaccine available for this virus and treatment is restricted to management of the opportunistic infections resulting from the immunosuppression caused by ATL (Tsukasaki et al., 2009 ).
Kaposi's sarcoma-associated herpesvirus (KSHV)
Kaposi'sarcoma (KS) is an angioproliferative tumor that was first described by the Hungarian pathologist Moritz Kaposi in 1872. KS lesions develop in connective tissues typically under the skin, giving rise to very characteristic purplish raised blotches because of the high vascularity of these lesions (Geilen et al., 2006) . Although most lesions remain asymptomatic, sometimes they can be disfiguring or painfully swollen, and KS lesions can be fatal if they develop in internal organs such as the lungs, liver or gastrointestinal tract (Levi, 2005) . This disease was traditionally considered rare, affecting elderly men of Mediterranean or Jewish origin and Northern African men (classic or sporadic KS) (Safai, 1987) . The incidence of this disease changed radically during the last few decades because of the widespread appearance of lymphoadenopathic KS cases in the sub-Saharan region in Africa (endemic KS), in transplanted patients undergoing immunosuppressive therapy (iatrogenic KS), and because of its tragic association with AIDS (epidemic KS) (Ganem, 2006) (Table 1 ). In fact, the description of a new, very aggressive variant of KS heralded the beginning of the worldwide AIDS epidemic (Wood and Harrington, 2005) . AIDS-KS is a life-threatening condition characterized by extensive local edema and disfiguring dermal lesions with involvement of the internal organs, oral cavity, bleeding and respiratory failure (Ganem, 2006) . Although the incidence of KS has been greatly reduced since the introduction of the triple antiretroviral therapy (HAART) for the treatment of HIV-infected individuals (Bower et al., 2006) , it still remains the most prevalent cancer in children in Africa, and is still more prevalent among minority groups and in developing countries.
KS lesions are histologically complex and are highly vascularized, containing proliferating spindle-shaped cells that are believed to be of endothelial origin, together with infiltrating mononuclear cells and abundant slit-like neovascular spaces (Ganem, 2006) . Although it was initially thought that HIV could be the causative agent of KS, intense research on AIDS and HIV-related malignancies during the early 1990s, however, led to the identification of a new human herpesvirus, HHV-8, as the etiological agent causing KS and two infrequent B-cell type lymphoproliferative diseases, primary effusion lymphoma (PEL) and multicentric Castleman's disease (Cesarman et al., 1995) . HHV-8, also know as KSHV, is a member of the gherpesviridae family and as such, the shedding of KSHV in saliva appears to be the most frequent route of transmission, as for other herpesviruses, including EBV (Ganem, 2006; Pauk et al., 2000) . The sequence of the KSHV genome revealed the presence of at least 89 openreading frames (ORFs), many of which are unique among the herpesviridae family (Russo et al., 1996) . Surprisingly, many of these KSHV genes represent pirated versions of cellular genes, including those encoding molecules involved in cell cycle control, apoptosis prevention, immune system regulation and inter-and intracellular communication, thus harboring proangiogenic and oncogenic potential (Russo et al., 1996) . As viral genes have historically represented powerful tools for disclosing critical cellular processes, the study of this angioproliferative tumor and its enigmatic causative virus and numerous candidate tumor-promoting genes may ultimately help to identify novel mechanisms involved in cell growth control and normal and tumor-induced angiogenesis.
KSHV and novel viral oncogenes
KSHV could be arguably considered the virus harboring the highest number of potential oncogenes. As for other herpesviruses, on infection and after multiple rounds of viral replication and spread, KSHV can enter into a latent viral program that in most cases lasts for the life of the individual or undergoes further lytic replication (Ganem, 2006) . In latency, the most frequent viral choice, only a few of the viral genes are expressed; also, the viral DNA is retained as a circular episome in the nucleus, and no or few virions are produced, thus often evading immune detection (Vider-Shalit et al., 2007) . It is not known what causes KSHV reactivation and reentry into a lytic cycle. Although treatment with phorbol esters can trigger the rapid replication of latently infected KSHV cells in vitro (Xie et al., 2008) , accumulating evidence suggests that cytokines and chemokines produced during chronic inflammatory processes in the case of classical KS, additional environmental factors, parasitic infection and compromised immune system in the case of endemic KS, and an interplay with HIV and its encoded proteins, particularly the HIV-Tat, combined with severe immunosupression in the epidemic KS, can ultimately promote latently KSHV-infected cells to reactivate the viral replicative program of KSHV. In every case, KS progression requires the evasion of the immune surveillance system, either by the deployment of a repertoire of KSHV viral strategies or by the inability of the host, to mount an appropriate immune response. This is supported by the ability to cause KS regression once the patient's immune system can fight back after the removal of immunosuppressive regimes, and in AIDS patients on successful treatment with HAART (Ganem, 2006) . Although most spindle cells within the KS lesions express exclusively latent viral genes, the presence of 1-5% of cells undergoing the lytic cycle appears to be a prerequisite for KS development, suggesting that an interesting interplay between latent infection gene programs and KSHV genes involved in lytic reactivation may underlie KS development (Chiou et al., 2002) .
Latently expressed KSHV genes
Owing to the destructive nature of the viral lytic cycle, in which infected cells are ultimately destined to die, genes expressed during latency were expected to hold the key to understanding KSHV sarcomagenesis. During the latent cycle, only a small portion of the KSHV-encoded genes is expressed (Zhong et al., 1996) . These include the viral genes LANA, vCyclin, vFlip, the ORF K12/Kaposin and a miRNA cluster, which are expressed in nearly 70% of the spindle cells in advanced KS lesions .
vCyclin is a virally encoded homolog of human cyclin D2 that forms functional complexes with cyclin-dependent kinase, which has broader substrate specificity than the endogenous complex and displays resistance to inhibition by the p16, p21 and p27 Cdk inhibitors (Sharp and Boshoff, 2000) . vCyclin/cyclin-dependent kinase complexes can even cause the degradation of p27 (Ellis et al., 1999) . The oncogenic potential of vCyclin can only be exposed, however, when p53 function is defective (Verschuren et al., 2002) because of the strong engagement of p53-dependent cell cycle arrest and apoptosis induced by vCyclin. In this regard, LANAmediated inhibition of p53 transcriptional activity (in this section) could provide an appropriate environment for vCyclin to exert its oncogenic function and contribute to KS progression in vivo.
vFlip is a viral homolog of the human FLICE inhibitory protein. By analogy with other FLICE inhibitory protein proteins encoded by other herpesvirus, it has been suggested that vFlip acts as an inhibitor for procaspase 8 activation during FasLtriggered apoptosis (Irmler et al., 1997) . This could result in immune privilege by endowing the infected cells with resistance to FasL and perhaps other deathreceptor ligands, such as those used by cytotoxic Tcells. vFlip can also stimulate the IKK complex leading to NF-kB activation (Field et al., 2003) , a process that has a key role in the survival of PEL cells (Keller et al., 2000) . vFlip is expressed in latently infected KS spindle cells and, as such, represents an ideal candidate for the growth-promoting role of KSHV (Ganem, 2006) . However, there is as yet no evidence that vFlip can cause endothelial cell transformation, except for the acquisition of a spindle phenotype in human umbilical endothelial cells expressing this protein (Grossmann et al., 2006) .
LANA is a large nuclear protein with no known mammalian homolog (Rainbow et al., 1997) . It is functionally similar to the EBV EBNA-1 protein, and is primarily implicated in the KSHV episomal persistence by tethering the KSHV episome to the host mitotic chromosomes through interactions with cellular chromosome-associated proteins (Cotter and Robertson, 1999) . Besides this crucial viral role, LANA dysregulates various cellular pathways involving the tumor suppressors pRb and p53 (Hu et al., 2002) . As such, LANA can cooperate with H-Ras to transform fibroblasts (Radkov et al., 2000) . LANA interacts with GSK3b, leading to the accumulation of cytoplasmatic and nuclear b-catenin (Fujimuro et al., 2003) and aberrant c-Myc stabilization (Bubman et al., 2007) .
However, despite the oncogenic potential of these latently expressed genes, it is unclear whether the expression of these genes is sufficient to cause cell transformation. An interesting possibility is that the combined expression of these genes provides a significant growth advantage, causing the latently infected KSHV cells to hyperproliferate in response to paracrine signals produced by other lytically infected or inflammatory cells. In this regard, it is possible to unmask their intrinsic oncogenic potential when endothelial cells expressing vCyclin and vFlip (and LANA, DM and JSGutkind, unpublished) are co-injected with a small number of cells expressing the potent KSHV-encoded oncogene vGPCR (Montaner et al., 2003) , thus likely recapitulating the interplay between latent and lytic KSHV genes often observed in KS lesions.
Kaposin B, one of the open-reading frames encoded by the poorly investigated KSHV latent gene K12, has the potential to cooperate with the major latent gene transcripts to induce sarcomagenesis, as its gene product binds and activates MK2 directly, and thus could stabilize mRNAs containing ARE sequences in their 3 0 UTRs, many of which are suspected to have a role in KS, such as IL-8 or TNF-a (McCormick and Ganem, 2005) .
KSHV miRNAs KSHV and other human herpesviruses also bear multiple small noncoding RNAs (miRNAs) that have recently been shown to modulate gene expression by mediating posttranscriptional targetspecific RNA interference (Cai et al., 2005) . In the case of KSHV, 17 distinct miRNAS encoded by 12 miRNA genes have been identified within the latency-associated transcript, but are not required for viral replication as judged by experiments with genetically modified KSHV viruses (Xu et al., 2006) . It has been hypothesized that the role of these miRNAs is to regulate antiviral cellular responses, and they could contribute to tumorigenesis by altering the expression of a number of host genes involved in immunomodulation, apoptosis and angiogenesis.
KSHV lytic genes
Histological evidence supports the invariable existence of a small portion (1-5%) of cells expressing KSHV lytic markers in KS lesions (Chiou et al., 2002) . However, it is unclear whether this cell population emerges from a basal level of cells undergoing the lytic viral cycle or results from the dysregulated expression of lytic genes, for example because of an aborted lytic program (Sodhi et al., 2004a) . Owing to the nature and the potential oncogenic properties of several of these genes, intense research has been conducted to address their specific roles in KS development.
vBcl-2 is distantly related to Bcl-2, but shares a high degree of homology to the conserved Bcl-2 homology domains BH1 and BH2 . vBcl-2 blocks apoptosis in diverse cellular systems as effectively as do Bcl-2 and Bcl-xL . Unlike some members of the Bcl-2 family of proteins, vBcl-2 is resistant to caspase-mediated conversion to a proapoptotic factor (Bellows et al., 2000) . Although overexpression of endogenous Bcl-2 is transforming in B lymphocytes (Chao and Korsmeyer, 1998) , a role for vBcl-2 in endothelial transformation has yet to be established.
vIRFs. Four IRFs have been identified in the KSHV genome. These molecules share limited but significant homology to the human IRF family of regulators of interferon signaling (Offermann, 2007) . vIRFs inhibit interferon-b-induced signaling leading to activation of the p21 tumor suppressor and the ATM/p53 pathway, and are able to induce fibroblast transformation (Offermann, 2007) . These molecules are highly expressed in B cells infected with KSHV, where they may help circumvent the antiviral immune response mediated by interferons (Seo et al., 2002) . vIRFs are not usually detected in spindle cells and KS lesions, and their relevance in Kaposi's sarcomagenesis is likely to be more limited .
Virally encoded cytokines and chemokines vCCL1, vCCL2, vCCL3) . KSHV encodes a homolog of the human IL-6 cytokine, vIL-6. vIL-6 is able to support the growth of a rat embryo fibroblast line that is dependent on IL-6 (Nicholas et al., 1997) . Unlike its cellular counterpart, vIL-6 does not require binding to the IL-6 receptor subunit, but instead is able to signal through the gp130-coreceptor subunit alone (Molden et al., 1997) . vIL-6 induces a potent transforming phenotype when expressed in murine fibroblast (Aoki et al., 1999) and leads to the expression of vascular endothelial growth factor (VEGF) (Aoki et al., 1999) . vIL-6 is expressed at low levels during latency, increasing during lytic replication both in PEL and endothelial cells (Staskus et al., 1999) . Besides its transforming ability, vIL-6 is induced by IFN-a in PEL cells and effectively blocks cell cycle arrest and apoptosis provoked by IFN-a, thereby protecting latently infected cells from this antiviral cytokine (Chatterjee et al., 2002) .
The genes for vCCL1, vCCL2 and vCCL3 (vMIPs) virally encoded chemokines are expressed during viral replication and appear to be involved in Th2 lymphocyte chemoattraction (Choi and Nicholas, 2008) . It has been postulated that vMIPs could produce a polarized immune response shielding from mounting effective Th1-driven antiviral responses (Choi and Nicholas, 2008) . vCCL2 acts as a non-signaling ligand with broad affinity for multiple CC and CXC receptors expressed in Th1 cells. By disrupting effective communication among innate and adaptive immune cells, the release of vMIPs could provide an effective immune evasion strategy for KSHV-infected cells. Interestingly, these virally encoded chemokines display proangiogenic properties through the induction of VEGF and possibly other factors (Dittmer and Kedes, 1998) , whereas their activation of the CCR8 receptor can be antiapoptotic and might therefore contribute to the counteraction of the tumor cell proapoptotic defenses of the host (Louahed et al., 2003) .
The KSHV vGPCR oncogene
Although the KSHV genome encodes multiple candidate oncogenes, extensive experimental information revealed that its virally encoded G protein-coupled receptor (GPCR) (KSHV GPCR) is unique in that it is both transforming and proangiogenic and can promote the tumoral growth of cells expressing KSHV latent genes in a paracrine manner (Arvanitakis et al., 1997; Bais et al., 1998; Montaner et al., 2003; Yang et al., 2000) . The KSHV GPCR is encoded by the ORF74, and its closest human homologs are CXCR1 and CXCR2, the receptors for IL-8/CXCL-8 and Gro-a/CXCL-1 chemokines (Arvanitakis et al., 1997) . KSHV GPCR, also often referred to as vGPCR, is constitutively active because of the presence of several structural changes, including a mutation (Asp142Val) within its DRY motif in the second intracytoplasmatic loop that is highly conserved among GPCRs (Rosenkilde et al., 2000) . Moreover, this receptor shows a higher degree of promiscuity than does its cellular homologs and is able to bind both CXC and CC chemokines, further enhancing its constitutive activity (Gershengorn et al., 1998) . Expression of this receptor is transforming in several cell types including fibroblasts and endothelial cells (Arvanitakis et al., 1997; Bais et al., 1998; Montaner et al., 2003) . Expression of vGPCR as a transgene or specifically in endothelial cells by a tissuespecific retroviral transduction system leads to the progressive development of KS-like lesions in multiple animal model systems (Jensen et al., 2005; Montaner et al., 2003; Yang et al., 2000) . Although the presence of mutant forms of GPCRs or heterotrimeric G proteins is not a frequent event in human cancer, several herpesviruses, including EVB, HHV-6, HHV-7 and hCMV-1, express one or multiple GPCRs from their viral genome, suggesting that these viruses might have evolved to harness the potent signaling capacity of GPCRs for their proliferative and replicative advantage (Dorsam and Gutkind, 2007; Rosenkilde et al., 2008) . In particular, vGPCR initiates the activity of a complex signaling network whose contribution to KS is beginning to be unraveled. vGPCR contributes to KS development through its potent transforming and proangiogenic functions. Among the multiple intracellular pathways stimulated by vGPCR, the Akt-mTOR signaling axis has recently taken center stage, as its activation contributes to KS development in genetically defined animal models (Sodhi et al., 2004b) . The pharmacological inhibition of mTOR by the use of rapamycin prevents KS progression in experimental model systems and represents a remarkably effective treatment option for renal transplanted patients who develop KS on immunosuppression (Stallone et al., 2005) . KSHV GPCR activates the Akt-mTOR by stimulating PI3 K through bg-subunits released from both pertussis-toxin-sensitive and -insensitive G proteins, as well as in an autocrine manner by upregulating the expression of the VEGF receptor VEGFR2/KDR and the concomitant release of VEGF (Bais et al., 2003) .
Although the stimulation of the Akt-mTOR biochemical route contributes to endothelial cell transformation by vGPCR, perhaps the most striking biological activity of this viral oncogene is to promote paracrine neoplasia. Indeed, only a very few of the spindle-like cells within the tumor mass express vGPCR even when KS-like lesions are initiated by the expression of vGPCR in endothelial cells on retroviral infection in vivo, (Montaner et al., 2003) . Although a hit-and-run process could explain the tumor-initiating activity of vGPCR and its subsequent loss as the tumor progresses, its decreased expression in inducible animal model systems (Grisotto et al., 2006) or the pharmacological ablation of vGPCR-expressing cells cause rapid tumor regression, even if the majority of the cells within the tumor do not express vGPCR and continue expressing KSHVlatent genes (Montaner et al., 2006) . At the molecular level, the angiogenic and paracrine transforming effect of vGPCR involves the activation of multiple mitogenactivated protein kinases and small GTPases of the Rho family whose activities converge in the nucleus to control transcription factors such as hypoxia-inducible factor 1a, AP-1 and NF-kB, thereby promoting the expression and secretion of proinflammatory cytokines such as VEGF, IL-6, IL-8/CXCL8 and MIP-1/CCL3 (Martin et al., 2008; Montaner et al., 2001; Montaner et al., 2004; Sodhi et al., 2000; Sodhi et al., 2001) . These, in turn, may recruit and promote the aberrant growth of KSHV-latent infected cells, as well as of multiple stromal and endothelial-derived cells and their progenitors, which constitute the majority of the cell populations in KS tumors (Montaner et al., 2003) (Figure 1) . Strikingly, these tumoral cells remain nonetheless dependent on the persistent secretion of growth and survival factors from vGPCR-expressing cells.
Conclusions
We now know that human tumor-associated viruses contribute to 10-15% of the cancers worldwide, or approximately 1.3 million new cancer cases each year. Hence, the opportunity exists to make remarkable progress in our fight against cancer at the global scale by preventing the spread of these viruses, by the development and distribution of effective and safe vaccines against them and by identifying the oncogenic mechanisms deployed by these viruses, thereby enabling the development of new treatment options for these virally associated human malignancies. Clearly, the study of how viruses hijack cell cycle regulatory and intracellular and even intercellular signaling mechanisms to achieve their replicative success continues to provide novel insights into multiple human diseases, including cancer. In this regard, although HBV and HCV infection contribute to HCC by promoting chronic inflammation, EBV and HTLV-1 appear to initiate pro-proliferative and immunomodulating signals through the activation of NF-kB and its transcriptional regulatory program. KSHV, the most recently identified human tumor-associated virus, harbors a surprising number of virally pirated genes, which contribute to immune evasion and promote the growth and survival of latently infected cells. This enigmatic angioproliferative disease also revealed the existence of a virally initiated process of paracrine transformation, which provides an excellent example of how cell populations expressing distinct gene programs can cooperate in tumor initiation, maintenance and dissemination. Indeed, intercellular and even interclonal cooperativity may not be limited to viralassociated tumors but are also likely to occur in some of the most prevalent and aggressive human neoplasias and their tumor-initiating stem cells. Ultimately, this cell-cell interdependence and their communication through cytokine and chemokine-initiated signaling networks can expose multiple molecular targets that can soon be Figure 1 Contribution of multiple oncogenic, proinflammatory and immune-evasive strategies for the development of KS in KSHVinfected cells. KS lesions are heterogeneous, composed of endothelial-derived spindle cells as well as multiple inflammatory and mesenchymal cells. Viral production occurs in a limited number (1-5%) of the KS cells that undergo lytic replication. Expression of the vGPCR oncogene in these cells and in cells aberrantly expressing lytic gene programs may contribute to sarcomagenesis because of the activation of a complex signaling network, including the NF-kB and Akt-mTOR pathways and multiple Rho GTPases and MAPKs, concomitant with the expression of potent proangiogenic, proinflammatory and chemoattractant factors such as the virally encoded vIL-6 and the vGPCR-induced secretion of IL-8, VEGF and Gro-a. These cytokines and chemokines promote the recruitment and proliferation of other latently infected endothelial-derived cells in a paracrine manner, in which the viral proteins vFlip, vCyclin and LANA provide a proliferative advantage. The host antiviral responses are inhibited by the antiapoptotic vIRFs and vBcl2 molecules, whereas the adaptive immune responses are evaded by the expression of multiple immunomodulatory molecules such as vMIPs.
exploited for the development of novel mechanism-based chemopreventive strategies and anticancer treatments.
Conflict of interest
The authors declare no conflict of interest.
